Olav Erich Yri

  • Post doc; PhD
  • +47 22 93 47 53

Original articles

Fiskvik I, Beiske K, Delabie J, Yri O, Spetalen S, Karjalainen-Lindsberg ML, Leppä S, Liestøl K, Smeland EB, Holte H (2014)
Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma
Leuk Lymphoma, 56 (6), 1742-9
DOI 10.3109/10428194.2014.970550, PubMed 25284491

Riihijärvi S, Fiskvik I, Taskinen M, Vajavaara H, Tikkala M, Yri O, Karjalainen-Lindsberg ML, Delabie J, Smeland E, Holte H, Leppä S (2014)
Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial
Haematologica, 100 (2), 238-45
DOI 10.3324/haematol.2014.113472, PubMed 25381134

Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H (2013)
Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab
Leuk Lymphoma, 54 (10), 2205-14
DOI 10.3109/10428194.2013.774392, PubMed 23391141

Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H (2012)
Polymorphisms in genes encoding interleukin-10 and drug metabolizing enzymes GSTP1, GSTT1, GSTA1 and UGT1A1 influence risk and outcome in Hodgkin lymphoma
Leuk Lymphoma, 53 (10), 1934-44
DOI 10.3109/10428194.2012.682307, PubMed 22475179

Wahlin BE, Yri OE, Kimby E, Holte H, Delabie J, Smeland EB, Sundström C, Christensson B, Sander B (2011)
Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times
Br J Haematol, 156 (2), 225-33
DOI 10.1111/j.1365-2141.2011.08942.x, PubMed 22126847

Yri OE, Torfoss D, Hungnes O, Tierens A, Waalen K, Nordøy T, Dudman S, Kilander A, Wader KF, Ostenstad B, Ekanger R, Meyer P, Kolstad A (2011)
Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment
Blood, 118 (26), 6769-71
DOI 10.1182/blood-2011-08-372649, PubMed 22058114

Randen U, Yri OE, Tierens A, Heim S, Beiske K, Delabie J (2011)
Mantle cell lymphoma with features of marginal-zone lymphoma
J Hematop, 4 (1), 7-11
DOI 10.1007/s12308-011-0084-x, PubMed 25089161

Yri OE, Bjoro T, Fossa SD (2005)
Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer
Eur Urol, 49 (1), 54-8; discussion 58
DOI 10.1016/j.eururo.2005.09.009, PubMed 16314038

Mellgren G, Børud B, Hoang T, Yri OE, Fladeby C, Lien EA, Lund J (2003)
Characterization of receptor-interacting protein RIP140 in the regulation of SF-1 responsive target genes
Mol Cell Endocrinol, 203 (1-2), 91-103
DOI 10.1016/s0303-7207(03)00097-2, PubMed 12782406

Lund J, Jacob A, Aesöy R, Yri OE, Mellgren G (1998)
Biochemical and functional analysis of nuclear receptors as targets in cAMP-dependent control of bovine CYP17
Endocr Res, 24 (3-4), 497-504
DOI 10.3109/07435809809032638, PubMed 9888530

Review articles

Daldorff S, Mathiesen RM, Yri OE, Ødegård HP, Geisler J (2016)
Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer
Br J Cancer, 116 (1), 10-20
DOI 10.1038/bjc.2016.405, PubMed 27923036

Other articles

Yri OE, Vig J, Hegstad E, Hovde O, Pignon I, Jynge P (2009)
Mangafodipir as a cytoprotective adjunct to chemotherapy--a case report
Acta Oncol, 48 (4), 633-5
DOI 10.1080/02841860802680427, PubMed 19169914

Page visits: 1041